News | August 07, 2014

Tryton Enrolls First Patient in the EXTENDED Access Registry

A single arm study designed to support FDA submission for U.S. approval

Tryton Side Branch Stent EXTENDED Access Registry

August 7, 2014 — Tryton Medical Inc. announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm clinical study of its Tryton Side Branch Stent. The Tryton IDE XA registry is designed to support FDA submission for U.S. approval and is expected to enroll 133 patients from Europe and the United States. Indulis Kumsars, M.D., P. Stradins University Hospital, Latvian Centre of Cardiology enrolled the first patient.

The Tryton IDE XA registry builds on the results of the TRYTON IDE Study, which showed the benefit of the Tryton Side Branch Stent in the intended population, complex bifurcation lesions involving significant (>2.25 mm RVD by QCA) side branches. The Tryton IDE XA Registry is designed to confirm these results in the intended population. Results from this registry together with the results from the Pivotal IDE Trial will be submitted to the U.S. Food and Drug Administration to seek approval of the device in the United States.

Martin Leon, M.D., FACC, professor of medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, and founder and chairman emeritus of the Cardiovascular Research Foundation, serves as principal investigator of the pivotal IDE trial and EXTENDED Access Registry.

"We look forward to the Extended Access Registry to confirm the improved outcomes observed in patients with complex bifurcation lesions involving significant side branches, the intended cohort of the TRYTON IDE Study,” said Leon. "I thank the EXTENDED Access Registry investigators for continuing to contribute to this important work."

“The Tryton Side Branch Stent allows me to treat complex bifurcation lesions in a predictable way securing the large side branch from onset of procedure,” said Kumsars. “I am excited to participate in this study that I expect to confirm the low Tryton peri?procedural MI rates in side branches larger than 2.25 mm, confirming the post?hoc analysis from the pivotal study.”

The Tryton Side Branch Stent is commercially available in Europe and parts of the Middle East, is investigational in the U.S. and is not available in Japan.

Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re?narrowing of the stented vessel following implantation. In patients undergoing PCI?stenting, approximately one?third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

For more information: www.bifurcationinstitute.com, www.trytonmedical.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init